Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients

BACKGROUND: The benefit of chemotherapy in colon cancer patients is well documented but depends largely on whether patients complete the planned treatment regimen. We evaluated predictors of early discontinuation (EDChemo) and dose reduction of chemotherapy, especially the role of adverse treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Boakye, Daniel, Jansen, Lina, Halama, Niels, Chang-Claude, Jenny, Hoffmeister, Michael, Brenner, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072866/
https://www.ncbi.nlm.nih.gov/pubmed/33995589
http://dx.doi.org/10.1177/17588359211006348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072866/
https://www.ncbi.nlm.nih.gov/pubmed/33995589
http://dx.doi.org/10.1177/17588359211006348

Ejemplares similares